The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients

• Published in: Respiratory investigation 2020-07, Vol.58 (4), p.269-274
• Main Authors: Tanaka, Miho, Hattori, Yoshihiro, Ishii, Tatsuya, Tohnai, Rie, Itoh, Shoichi, Kawa, Yoshitaka, Kono, Yuko, Urata, Yoshiko, Satouchi, Miyako
• Format: Article
• Language: English
• Subjects: Albumin-bound paclitaxel; Carboplatin; Non-small cell lung cancer; Second-line treatment
• ISSN: 2212-5345; 2212-5353
• DOI: 10.1016/j.resinv.2019.12.008

Carboplatin plus nanoparticle albumin-bound paclitaxel (nab-PTX) is one of the available first-line treatments for non-small cell lung cancer (NSCLC) patients. However, the efficacy of carboplatin plus nab-PTX as second-line, remains unknown. We examined the efficacy of carboplatin plus nab-PTX after cisplatin plus pemetrexed in non-squamous NSCLC patients. We retrospectively reviewed advanced non-squamous NSCLC patients who received carboplatin plus nab-PTX as a second-line chemotherapy regimen after cisplatin plus pemetrexed in our hospital between March 2013 and December 2017. We assessed clinical characteristics, efficacy, and toxicities. Forty-four patients were recruited. The overall response rate (ORR) was 29% and the disease control rate (DCR), 69%. The median progression-free survival (mPFS) was 3.7 months (95% CI: 2.4–5.5 months) and the median overall survival, 16.6 months (95% CI:8.8–19.5 months). We assessed the ORR and mPFS using the best overall response in the prior regimen. The ORR and mPFS were better in the PD group (ORR; 44% and mPFS: 5.6 months). Carboplatin plus nab-PTX after cisplatin plus pemetrexed in non-squamous NSCLC patients is a treatment option. There were several cases where cisplatin plus pemetrexed was not effective, but Carboplatin plus nab-PTX was.